Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

We examined whether neuropsychiatric symptoms (NPS) interact with cerebrospinal fluid (CSF) biomarkers (amyloid-β42 [Aβ42], tau, phosphorylated tau181 [ptau181], tau/Aβ42, and ptau181/Aβ42) of Alzheimer's disease pathology to predict driving decline among cognitively-normal older adults (N=116) aged ≥65. Cox proportional hazards models examined time to receiving a rating of marginal or fail on the driving test. Age, education, and gender were adjusted in the models. Participants with more abnormal CSF (Aβ42, tau/Aβ42, ptau181/Aβ42) and NPS were faster to receive a marginal/fail on the road test compared to those without NPS. NPS interact with abnormal CSF biomarkers to impact driving performance among cognitively-normal older adults.

Original languageEnglish
Pages (from-to)675-680
Number of pages6
JournalJournal of Alzheimer's Disease
Volume58
Issue number3
DOIs
StatePublished - 2017

Keywords

  • Alzheimer's disease
  • cerebrospinal fluid
  • depression
  • neuropsychology
  • noncognitive outcomes
  • preclinical

Fingerprint Dive into the research topics of 'Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report'. Together they form a unique fingerprint.

Cite this